SCHEMBL2833030

SCHEMBL2833030

COc1cc(C)c(S(=O)(=O)N2c3ccccc3CC2COc2ccnc(Cl)n2)c(C)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.38
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
ALDH1A1 P00352 3/20 0.36
LMNA P02545 3/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
NPSR1 Q6W5P4 2/20 0.36
MCL1 Q07820 3/20 0.35
BAK1 Q16611 2/20 0.35
PSEN1 P49768 1/20 0.34
PSEN2 P49810 1/20 0.34
APH1B Q8WW43 1/20 0.34
NCSTN Q92542 1/20 0.34
APH1A Q96BI3 1/20 0.34
PSENEN Q9NZ42 1/20 0.34
KMT2A Q03164 2/20 0.33
RECQL P46063 1/20 0.33
BCL2L1 Q07817 1/20 0.33
GPR84 Q9NQS5 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2833025 1.00 TSHR (0.38) TSHRCRHBPCRHR2ALDH1A1LMNA
SCHEMBL2360574 0.87 CA12 (0.38) TSHRCRHBPCRHR2ALDH1A1LMNA
SCHEMBL2836529 0.84 CA12 (0.38) TSHRCRHBPCRHR2ALDH1A1KMT2A
SCHEMBL2834634 0.82 HTR1A (0.40)
SCHEMBL2832998 0.82 HTR1A (0.40)
SCHEMBL12150081 0.81 BDKRB1 (0.39) ALDH1A1
SCHEMBL2836242 0.81 HTR1A (0.36) TSHRCRHBPCRHR2ALDH1A1PSEN1
SCHEMBL2835372 0.80 HTR1A (0.35) TSHRCRHBPCRHR2ALDH1A1KMT2A
SCHEMBL2200125 0.79 TSHR (0.46) TSHRCRHBPCRHR2ALDH1A1LMNA
SCHEMBL2200120 0.79 TSHR (0.46) TSHRCRHBPCRHR2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2356101-B1 PYRIMIDINE- AND TRIAZINE-SULFONAMIDE DERIVATIVES AS BRADYKININ B1 RECEPTOR (B1R) INHIBITORS FOR THE TREATMENT OF PAIN GRUENENTHAL GMBH (DE) 2013-02-27 EP disclosed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US disclosed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds ADORA2B, CCNB1, TYMS TSHR 370/4885CRHBP 3317/4885CRHR2 1990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.